Pörssitiedote09.11.2023 klo 23.15RLS Global AB: RLS Global initiates strategic review process aiming to commercialize ChloraSolv
Pörssitiedote09.11.2023 klo 23.00RLS Global AB: RLS Global and Convatec have agreed to terminate collaboration agreement
Lehdistötiedote06.09.2023 klo 10.00RLS Global AB: First patient included in new clinical investigation on pressure ulcers
Lehdistötiedote01.09.2023 klo 14.00RLS Global AB: ChloraSolv recommended for UK CA certification required for UK market after Brexit
Pörssitiedote25.08.2023 klo 10.00RLS Global AB: RLS GLOBAL AB (publ) PUBLISHES INTERIM REPORT FOR THE PERIOD APRIL-JUNE 2023
Pörssitiedote24.08.2023 klo 19.30RLS Global AB: RLS GLOBAL AB (PUBL) RAISES A SHORT-TERM LOAN OF MSEK 5.0
Pörssitiedote22.08.2023 klo 16.00RLS Global AB: RLS Global appoints Torbjörn Sannerstedt as new Chief Financial Officer
Lehdistötiedote01.06.2023 klo 13.55Redeye: RLS Global Q1 2023: Delay in Europe but progress in the Middle East
Lehdistötiedote20.03.2023 klo 12.00RLS Global AB: ChloraSolv shows notably greater antibiofilm activity in vitro compared to other debridement products in published article
Lehdistötiedote01.03.2023 klo 15.48Redeye: RLS Global Q4 2022 - No surprises – but expectations of an eventful 2023
Pörssitiedote24.01.2023 klo 22.40Lars Johansson nominated as new Chairman of the Board of RLS Global AB
Lehdistötiedote09.12.2022 klo 10.00RLS Global AB: RLS Global: The rights issue is registered and the trading in Paid Subscription Shares ceases
Lehdistötiedote10.11.2022 klo 12.00Presentation by Björn Larsson, CEO, RLS Global AB, about the company's operations and the currently ongoing rights issue
Lehdistötiedote04.11.2022 klo 15.30RLS Global AB: RLS Global's CEO Björn Larsson interviewed by Erik Penser Bank about the ongoing rights issue